HTHanna-Riikka Teppo

Hanna-Riikka Teppo

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Hanna-Riikka Teppo has a total of 100 co-authors. Here are the top co-authors by number of shared publications:

  • Kirsi-Maria Haapasaari

    Cancer Research and Translational Medicine Research Unit, University of Oulu, Oulu, Finland

    6 shared publications
  • Outi Kuittinen

    Department of Oncology and Radiotherapy and Medical Research Center

    5 shared publications
  • Outi Kuittinen

    Faculty of Health Medicine, Institute of Clinical Medicine University of Eastern Finland Kuopio Finland

    5 shared publications
  • Peeter Karihtala

    Department of Oncology, Helsinki University Hospital Comprehensive Cancer Center and University of Helsinki, Helsinki, Finland

    5 shared publications
  • Taina Turpeenniemi-Hujanen

    Cancer Research and Translational Medicine Research Unit, University of Oulu, 90220 Oulu, Finland; Department of Oncology and Radiotherapy, Oulu University Hospital, 90029 Oulu, Finland

    5 shared publications
  • Bijay Ratna Shakya

    Research Unit of Health Sciences and Technology, Faculty of Medicine, University of Oulu, Oulu, Finland

    4 shared publications

Latest Publications

  • Open Access

    Correction: Häyrinen et al. The Transcription Factor Twist1 Has a Significant Role in Mycosis Fungoides (MF) Cell Biology: An RNA Sequencing Study of 40 MF Cases. Cancers 2023, 15, 1527

    by Marjaana J. Häyrinen, Jenni Kiiskilä, Annamari Ranki, Liisa Väkevä, Henry J. Barton, Milla E. L. Kuusisto, Katja Porvari, Hanne Kuitunen, Kirsi-Maria Haapasaari, Hanna-Riikka Teppo, et al.

  • Tumor RNA Sequencing Identifies a Group of Patients with Mycosis Fungoides with Failure of Skin-Directed Therapies

    by Marjaana Häyrinen, Hanna-Riikka Teppo, Liisa Väkevä, Annamari Ranki, Henry J. Barton, Katja Porvari, Jenni Kiiskilä, Milla E.L. Kuusisto, Hanne Kuitunen, Siria Lemma, et al.


  • Open Access

    The Transcription Factor Twist1 Has a Significant Role in Mycosis Fungoides (MF) Cell Biology: An RNA Sequencing Study of 40 MF Cases

    by Marjaana J. Häyrinen, Jenni Kiiskilä, Annamari Ranki, Liisa Väkevä, Henry J. Barton, Milla E. L. Kuusisto, Katja Porvari, Hanne Kuitunen, Kirsi-Maria Haapasaari, Hanna-Riikka Teppo, et al.

    The purpose of this RNA sequencing study was to investigate the biological mechanism underlying how the transcription factors (TFs) Twist1 and Zeb1 influence the prognosis of mycosis fungoides (MF). We used laser-captured microdissection to dissect malignant T-cells obtained from 40 skin biopsies from 40 MF patients with stage I–IV disease. Immunohistochemistry (IHC) was used to determinate the protein expression levels of Twist1 and Zeb1. Based on RNA sequencing, principal component analysis (PCA), differential expression (DE) analysis, ingenuity pathway analysis (IPA), and hub gene analysis were performed between the high and low Twist1 IHC expression cases. The DNA from 28 samples was used to analyze the TWIST1 promoter methylation level. In the PCA, Twist1 IHC expression seemed to classify cases into different groups. The DE analysis yielded 321 significant genes. In the IPA, 228 significant upstream regulators and 177 significant master regulators/causal networks were identified. In the hub gene analysis, 28 hub genes were found. The methylation level of TWIST1 promoter regions did not correlate with Twist1 protein expression. Zeb1 protein expression did not show any major correlation with global RNA expression in the PCA. Many of the observed genes and pathways associated with high Twist1 expression are known to be involved in immunoregulation, lymphocyte differentiation, and aggressive tumor biology. In conclusion, Twist1 might be an important regulator in the disease progression of MF.


  • Open Access

    Pan-cancer scale screening reveals NRF2 associated immunoevasive characteristics in non-small cell lung cancer and squamous malignancies

    by Jouni Härkönen, Petri Pölönen, Ashik Jawahar Deen, Ilakya Selvarajan, Hanna-Riikka Teppo, Elitsa Y Dimova, Thomas Kietzmann, Maarit Ahtiainen, Tiia Eklund, Teijo Kuopio, et al.

    Summary: The NRF2 pathway is frequently activated in various cancer types, yet a comprehensive analysis of its effects across different malignancies is currently lacking. We developed a robust NRF2 activity metric and utilized it to conduct a pan-cancer wide analysis of oncogenic NRF2 signaling. We identified a distinct immunoevasive phenotype where high NRF2 activity is associated with low interferon-gamma (IFNγ), HLA-I expression and T-cell infiltration spanning non-small cell lung cancer (NSCLC) and squamous malignancies of head and neck area, cervix and esophagus. In squamous cell cancers, NRF2 overactive tumors comprise a molecular phenotype with SOX2 / TP63 amplification, TP53 mutation and CDKN2A loss. These immune-cold NRF2 hyperactive diseases are associated with upregulation of immunomodulatory NAMPT, WNT5A, SPP1, SLC7A11 and SLC2A1 that represent candidate NRF2 target genes, suggesting direct modulation of the tumor immune milieu. Based on single-cell mRNA data, coupled with a priori information on intercellular ligand-receptor interactions, cancer cells of this subtype exhibit decreased expression of IFNγ responsive ligands, and increased expression of immunosuppressive ligands NAMPT, SPP1 and WNT5A that mediate signaling in intercellular crosstalk. As we observed differential cytokine mRNA expression with IFNγ treatment in NSCLC adenocarcinoma subtype, we explored the cytokine secretome in vitro . We found that secreted neutrophil chemoattractants interleukin-8 ( CXCL8 ) and ENA-78 ( CXCL5 ) are elevated in NRF2 overactive cells, suggesting contribution of immunosuppressive neutrophils in NRF2 driven immune escape. Importantly, as overactive NRF2 is associated with immune-cold characteristics, our results highlight the utility of NRF2 pathway activation as a putative biomarker for stratifying immune-checkpoint blockade responders and non-responders across NSCLC and squamous cancers. Abstract Figure:

  • Open Access

    Optimization of measurement mode and sample processing for FTIR microspectroscopy in skin cancer research

    by Bijay Ratna Shakya, Hanna-Riikka Teppo, Lassi Rieppo

    The spectra of identical samples measured in two different modes and with or without paraffin show a significant difference. The paraffinized samples measured in transflection mode showed the best accuracy in discriminating two melanoma cell lines.


  • Open Access

    NRF3 Decreases during Melanoma Carcinogenesis and Is an Independent Prognostic Marker in Melanoma

    by Anni Immonen, Kirsi-Maria Haapasaari, Sini Skarp, Peeter Karihtala, Hanna-Riikka Teppo

    The prognostic significance of the major redox regulator, nuclear factor erythroid‐2‐related factor 2 (NRF2), is recognized in many cancers, but the role of NRF3 is not studied. Analysis from the Gene Expression Omnibus datasets showed that NRF3 mRNA levels increased from benign to dysplastic naevi (p = 0.04). We characterized the immunohistochemical expression of NRF3 in 81 naevi, 67 primary skin melanomas, and 51 lymph node metastases. The immunohistochemical expression of cytoplasmic NRF3 decreased from benign to dysplastic naevi (p < 0.001) and further to primary melanomas (p < 0.001). High cytoplasmic NRF3 protein expression in pigment cells of the primary melanomas associated with worse melanoma‐specific survival in multivariate analysis, specifically in the subgroup of patients with the lymph node metastases at the time of diagnosis (hazard ratio 3.179; 95% confidence interval 1.065‐9.493; p = 0.038). Intriguingly, we did not observe associations between NRF3 and the traditional prognostic factors such as Breslow thickness, ulceration, or stage. Together, this data represents the primary description about the role of NRF3 in pigment tumours that is worthy of further explorations.


  • Incidence and clinicopathological features of Follicular T-cell lymphoma in Finland: a population-based immunohistochemical study

    by Jenni Kiiskilä, Pyry Uotila, Kirsi-Maria Haapasaari, Saila Kauppila, Hanna-Riikka Teppo, Milla E.L. Kuusisto, Siria Lemma, Taina Turpeenniemi-Hujanen, Martine Vornanen, Mine Eray, et al.


  • Open Access

    Different chemokine profile between systemic and testicular diffuse large B-cell lymphoma

    by Riina K. Ollikainen, Pyry H. Kotkaranta, Janette Kemppainen, Hanna-Riikka Teppo, Hanne Kuitunen, Risto Pirinen, Taina Turpeenniemi-Hujanen, Outi Kuittinen, Milla E.L. Kuusisto

    Although treatment for diffuse large B-cell lymphoma (DLBCL) has taken some notable steps in the 2000s, there are still subgroups of patients suffering from high mortality and relapse rates. To further improve treatment outcomes, it is essential to discover new mechanisms of chemotherapy resistance and create new treatment approaches to overcome them. In the present study, we analyzed the expression of chemokines and their ligands in systemic and testicular DLBCL. From our biopsy sample set of 21 testicular and 28 systemic lymphomas, we were able to demonstrate chemokine profile differences and identify associations with clinical risk factors. High cytoplasmic CXCL13 expression had correlations with better treatment response, lower disease-related mortality, and limited stage. This study suggests that active CXCR5/CXCL13 signaling could overtake the CXCR4/CXCL12 axis, resulting in a better prognosis.


  • Open Access

    Testis‐Specific Thioredoxins TXNDC2, TXNDC3, and TXNDC6 Are Expressed in Both Testicular and Systemic DLBCL and Correlate with Clinical Disease Presentation

    by Mikko C. Chan, Janette Savela, Riina K. Ollikainen, Hanna-Riikka Teppo, Ilkka Miinalainen, Risto Pirinen, Esa J. M. Kari, Hanne Kuitunen, Taina Turpeenniemi-Hujanen, Outi Kuittinen, et al.

    DLBCL is the most common type of non‐Hodgkin lymphoma with a substantial group of patients suffering a poor prognosis. Therefore more specific markers are required for better understanding of disease biology and treatment. This study demonstrates that testis‐specific antioxidant enzymes TXNDC2, TXNDC3, and TXNDC6 alongside oxidative stress marker 8‐OHdG are expressed in both testicular and systemic DLBCL, and their presence or absence has correlations with clinical risk factors such as the number of extranodal effusion, the appearance of B‐symptoms, and treatment response. Biopsy samples were collected from 28 systemic and 21 testicular male DLBCL patients. The samples were histostained with TXNDC2, TXNDC3, TXNDC6, and 8‐OHdG, then graded by a hematopathologist blinded to clinical data. Immunoelectron microscopy was used as a second method to confirm the reliability of the acquired immunohistochemistry data. The absence of nuclear TXNDC2 expression in testicular DLBCL cells correlated with worse primary treatment response, cytoplasmic TXNDC3 expression in testicular and systemic DLBCL associated with lower frequency of B‐symptoms, and TXNDC6 expression in cytoplasm in systemic DLBCL had a clinical significance with higher LD levels suggesting a role in the biological nature of these lymphomas. Overall, TXNDC3 cytoplasmic expression is correlated with a more positive outcome in both testicular and systemic DLBCL, while TXNDC6 cytoplasmic expression is associated with a negative outcome in systemic DLBCL.